The use of recombinant coagulation factor VIIa in uncontrolled postoperative bleeding in children undergoing cardiac surgery with cardiopulmonary bypass

Pediatric Critical Care Medicine

Volumn 5, Issue 3, 2004, Pages 246-250

  Pychyńska Pokorska, Magdalena ^a   Moll, Jacek Jan ^a   Krajewski, Wojciech ^a   Jarosik, Piotr ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Bleeding; Cardiac surgery; Cardiopulmonary bypass; Children; Congenital heart disease; Recombinant coagulation FVIIa

Indexed keywords

BLOOD CLOTTING FACTOR 7; FIBRINOGEN; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ARTICLE; BLOOD; CARDIOPULMONARY BYPASS; CHILD; CLINICAL TRIAL; FEMALE; HEART SURGERY; HUMAN; INFANT; MALE; METABOLISM; NEWBORN; PARTIAL THROMBOPLASTIN TIME; POSTOPERATIVE HEMORRHAGE; PRESCHOOL CHILD; PROTHROMBIN TIME; THROMBOCYTE COUNT;

CARDIAC SURGICAL PROCEDURES; CARDIOPULMONARY BYPASS; CHILD; CHILD, PRESCHOOL; FACTOR VII; FEMALE; FIBRINOGEN; HEMOSTATICS; HUMANS; INFANT; INFANT, NEWBORN; MALE; PARTIAL THROMBOPLASTIN TIME; PLATELET COUNT; POSTOPERATIVE HEMORRHAGE; PROTHROMBIN TIME; RECOMBINANT PROTEINS;

EID: 5144229513     PISSN: 15297535     EISSN: 19473893     Source Type: Journal    
DOI: 10.1097/01.PCC.0000123546.78900.67     Document Type: Article

References (13)

1. Hedner U, Erhardtsen E: Potential role for rFVIIa in transfusion medicine. Transfusion 2002; 42:114-124
2. Hendriks HG, van der Maaten JM, de Wolf J, et al: An effective treatment of severe intractable bleeding after valve repair by one single dose of activated recombinant factor VII. Anesth Analg 2001; 93:287-289
3. Tobias JD, Berkenbosch JW, Russo P: Recombinant factor VIIa to treat bleeding after cardiac surgery in an infant. Pediatr Crit Care Med 2003; 4:49-51
4. Tobias JD, Groeper K, Berkenbosch JW: Preliminary experience with the use of recombinant factor VIIa to treat coagulation disturbances in pediatric patients. South Med J 2003; 96:12-16
5. Zietkiewicz M, Garlicki M, Domagala J, et al: Successful use of activated recombinant factor VII to control bleeding abnormalities in a patient with a left ventricular assist device. J Thorac Cardiovasc Surg 2002; 123:384-385
6. Kastrup M, von Heymann C, Hotz H, et al: Recombinant factor VIIa after aortic valve replacement in a patient with osteogenesis imperfecta. Ann Thorac Surg 2002; 74:910-912
7. Al Douri M, Shafi T, Al Khudairi D, et al: Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery. Blood Coagul Fibrinolysis 2000; 11:S121-S127
8. Postoperative care. In: Kirklin/Barratt-Boyes Cardiac Surgery. Terry D (Ed). New York, Churchill Livingstone, 1993, pp 222-225
9. Despotis GJ, Avidan MS, Hogue CW Jr: Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 2001; 72:S1821-S1831
10. Moulton MJ, Creswell LL, Mackey ME, et al: Reexploration for bleeding is a risk factor for adverse outcomes after cardiac operations. J Thorac Cardiovasc Surg 1996; 111: 1037-1046
11. Manno CS, Hedberg KW, Kim HC, et al: Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children. Blood 1991; 77:930-936
12. Laupacis A, Fergusson D: Drugs to minimize perioperative blood loss in cardiac surgery: Meta-analyses using perioperative blood transfusion as the outcome. The International Study of Peri-Operative Transfusion (ISPOT) Investigators. Anesthesia Analgesia 1997; 85:1258-1267
13. Monroe DM, Hoffman M, Oliver JA, et al: Platelet activity of high-dose factor VIIa is independent of tissue factor: Br J Haematol 1997; 99:542-547